This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gold, D. V. Articles by Sharkey, R. M. Search for Related Content PubMed PubMed Citation Articles by Gold, D. V. Articles by Sharkey, R. M.

Targeting of Xenografted Pancreatic Cancer with a New Monoclonal Antibody, PAM4¹

Center for Molecular Medicine and Immunology and The Garden State Cancer Center, Newark, New Jersey 07103

We have examined the ability of murine monoclonal antibody PAM4, directed against a pancreatic cancer-derived mucin, to target human pancreatic cancers carried as xenografts in athymic nude mice. Four tumor lines were used representing the range of expected differentiation; CaPan1, AsPc1, Hs766T, and BxPc3. In each case tumor uptake of PAM4 (range, 21–48% injected dose/g on day 3) was significantly higher than concomitantly administered, nonspecific, isotype-matched Ag8 antibody (range, 3.6–9.3% injected dose/g on day 3). Based upon the biodistribution data the estimated potential radiation dose delivered to the tumors when normalized to the blood dose as an estimate of dose-limiting myelotoxicity would be 13.1-, 2.2-, 3.4-, and 3.3-fold higher than to blood, respectively. PAM4 showed no evidence of targeting to normal tissues, except within the CaPan1 tumor model, where a small but consistent splenic uptake was observed. Splenic targeting was abolished by use of an increased PAM4 protein dose. Targeting of PAM4 to other normal tissues was not affected by the increased protein dose; however, tumor uptake of PAM4 (percentage of injected dose/g) was significantly increased by as much as 3-fold. The ability of PAM4 to target the CaPan1 tumor compared favorably to that of MN14, an anti-carcinoembryonic antigen murine monoclonal antibody. Tumor uptake of PAM4 was much greater than that for MN14 at days 1 and 3, whereas at later time points equivalent accumulations of activity were noted. Estimates of potential radiation doses to the tumor when normalized to the blood dose were 3.0 for MN14 and 9.6 for PAM4. These studies have shown that PAM4 is able to target pancreatic cancer with high specificity, achieving high concentrations at the tumor site. A rationale exists, then, for the performance of a clinical trial of radiolabeled PAM4 in the detection and localization of pancreatic cancer.

¹ Supported in part by Grant CA54425 from the NIH and a grant from the Robert Leet and Clara Guthrie Patterson Trust.

² To whom requests for reprints should be addressed.

Received 9/22/94. Accepted 12/29/94.

This article has been cited by other articles:

				D. V. Gold, D. M. Goldenberg, H. Karacay, E. A. Rossi, C.-H. Chang, T. M. Cardillo, W. J. McBride, and R. M. Sharkey A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma Cancer Res., June 15, 2008; 68(12): 4819 - 4826. [Abstract] [Full Text] [PDF]

				T. M. Cardillo, H. Karacay, D. M. Goldenberg, D. Yeldell, C.-H. Chang, D. E. Modrak, R. M. Sharkey, and D. V. Gold Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy Clin. Cancer Res., May 15, 2004; 10(10): 3552 - 3561. [Abstract] [Full Text] [PDF]

				D. V. Gold, K. Schutsky, D. Modrak, and T. M. Cardillo Low-Dose Radioimmunotherapy (90Y-PAM4) Combined with Gemcitabine for the Treatment of Experimental Pancreatic Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3929S - 3937. [Abstract] [Full Text] [PDF]

				K. Kawakami, M. Kawakami, S. R. Husain, and R. K. Puri Targeting Interleukin-4 Receptors for Effective Pancreatic Cancer Therapy Cancer Res., July 1, 2002; 62(13): 3575 - 3580. [Abstract] [Full Text] [PDF]

				T. M. Cardillo, Z. Ying, and D. V. Gold Therapeutic Advantage of 90Yttrium- versus131Iodine-labeled PAM4 Antibody in Experimental Pancreatic Cancer Clin. Cancer Res., October 1, 2001; 7(10): 3186 - 3192. [Abstract] [Full Text] [PDF]